menu
    • menu

    Company profile for SkinJect

    NEW Drugs in Dev: 3
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    SkinJect is a groundbreaking drug delivery system where the needles themselves are the drug. The device uses a dissolvable microneedle array (MNA) to deliver chemotherapy directly into the top layer of the skin, targeting non-melanoma skin cancer. This localized delivery not only kills cancer cells but also triggers a beneficial immune response.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SkinJectUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    285 Kappa Drive, Suite 100, Pittsburgh PA 15238
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.skinjectpatch.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/skinject
    youtube
    YouTube
    Twitter
    Twitter
    https://twitter.com/SkinJectPatch

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Medicus Pharma Advances SkinJect into Registrational Development
    Medicus Pharma Advances SkinJect into Registrational Development

    03 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/03/3305990/0/en/medicus-pharma-advances-skinject-into-registrational-development-for-gorlin-syndrome.html

    GLOBENEWSWIRE
    03 Jun 2026
    Share Share
    Medicus Pharma Seeks FDA Orphan Drug Designation For Skinject
    Medicus Pharma Seeks FDA Orphan Drug Designation For Skinject

    19 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7187515

    FIRSTWORD PHARMA
    19 Apr 2026
    Share Share
    Medicus Pharma Ltd Clarifies Positive Skinject Phase 2 Dataset
    Medicus Pharma Ltd Clarifies Positive Skinject Phase 2 Dataset

    01 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/01/3266511/0/en/Medicus-Pharma-Ltd-Clarifies-Positive-SkinJect-Phase-2-Dataset.html

    GLOBENEWSWIRE
    01 Apr 2026
    Share Share
    Medicus SkinJect Ph2 Shows 80% ORR With KOL Validation
    Medicus SkinJect Ph2 Shows 80% ORR With KOL Validation

    30 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/30/3264524/0/en/Medicus-Pharma-Reports-KOL-Validation-of-SkinJect-Phase-2-Data-of-80-Overall-Response-Rate.html

    GLOBENEWSWIRE
    30 Mar 2026
    Share Share
    Medicus Pharma: 80% ORR in Phase 2 SkinJect, Unveils AI Platform
    Medicus Pharma: 80% ORR in Phase 2 SkinJect, Unveils AI Platform

    26 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/26/3262893/0/en/Medicus-Pharma-Business-Update-Call-to-Highlight-80-Overall-Response-Rate-ORR-in-Phase-2-SkinJect-Study-and-Agentic-AI-enabled-Drug-Development-Plan.html

    GLOBENEWSWIRE
    26 Mar 2026
    Share Share
    Medicus Pharma To Present Skinject(R) Phase 2 Results
    Medicus Pharma To Present Skinject(R) Phase 2 Results

    18 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-18/medicus-pharma-to-discuss-positive-skinject-r-phase-2-topline-results-in-fireside-chat-hosted-by-br

    PHARMIWEB
    18 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search